Understanding the role of CD44V6 in ovarian cancer

HUI-FENG ZHANG, PENG HU and SHENG-QUAN FANG

Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, Hubei 430070, P.R. China

Received September 6, 2016; Accepted March 10, 2017

DOI: 10.3892/ol.2017.6377

Abstract. This study examined the association of CD44V6 expression in ovarian cancer. We recruited 38 patients with ovarian cancer, 23 with benign ovarian tumor, and 20 with normal ovaries using RT-PCR and western blot analysis. Compared with normal ovaries, the expression of CD44V6 mRNA was significantly elevated in benign ovarian tumor and ovarian cancer. At the protein level, we found no significant differences in CD44V6 expression between normal ovarian tissue and benign ovarian tumor. However, the expression of CD44V6 in ovarian cancer was significantly elevated compared to normal ovaries and benign ovarian tumor. These results were supported by ELISA and western blot analysis. Immunohistochemistry showed that CD44V6 protein in ovarian cancer cells accumulated at high levels on the membrane of ovarian cancer cells. CD44V6 expression is closely associated with the tumorous transformation of ovarian tissue, suggesting that CD44V6 can promote the occurrence and progression of ovarian cancer.

Patients and methods

Patient data. We recruited 38 patients, admitted to the Hubei Cancer Hospital (Hubei, China), who received gynecological surgery for ovarian cancer from February 2014 to February, 2015. This experimental group had an average age of 45.4 years. We also recruited 23 patients with benign ovarian tumor with an average age of 43.4 years and 20 with normal ovarian tissue with an average age of 44.3 years. The patients with ovarian cancer were diagnosed according to the Ovarian Cancer International Federation of Gynecology and Obstetrics. Exclusion criteria for the study were: Patients with other related gynecological diseases such as cervical and endometrial cancer. This study was approved by the Ethics Committee of Hubei Cancer Hospital. Signed written informed consents were obtained from all participants before the study.

RNA extraction from ovarian cancer cells. Ovarian samples were kept in liquid nitrogen at °C until needed, then 0.1 g, was placed on ice, to which 0.6 ml of RNA Plus was added (Takara Bio, Dalian, China). Samples were ground quickly in precooled mortar and homogenates were transferred to 1.5 ml tube, washed with 0.3 ml of RNA Plus, and transferred to a centrifuge tube, after which 200 µl of chloroform was added, agitated for 15 sec and incubated on ice for 15 min. We centrifuged samples at 10,000 x g for 15 min at 4°C. The supernatant was transferred to a tube without RNase, and equivalent isopropanol was added, mixed, and incubated on ice for 10 min, then centrifuged again at 1,000 x g for 15 min at 4°C. The supernatant was removed and 750 µl of 75% ethanol was added, with gentle mixing and centrifugation at 10,000 x g for 10 min at 4°C. The precipitate was transferred to a tube, washed with 0.3 ml of 75% ethanol, and dried in a vacuum centrifuge on ice for 15 min. The dried samples were dissolved in 50 µl of RNase-free water and RT-PCR was performed.

Correspondence to: Dr Sheng-Quan Fang, Department of Gynecologic Oncology, Hubei Cancer Hospital, 116 Zhuodaquan South Road, Wuhan, Hubei 430070, P.R. China
E-mail: uprf_2247@163.com

Key words: CD44V6, ovarian cancer, RT-PCR, enzyme-linked immunosorbent assay, correlation
4˚C. The supernatant was then removed. RNase-free water was added and the total RNA was measured.

**Fluorogenic quantitative PCR.** The procedure was conducted according to Takara fluorogenic quantitative PCR instructions, with some modifications (11). The primers for fluorogenic quantitative PCR were synthesized by Suzhou Jinweizhi Biotechnology (Suzhou, China) and the sequences are shown in Table I.

**ELISA.** We conducted enzyme-linked immunosorbent assay (ELISA) following the instructions of the ELISA kit (Takara Company) with minor modifications (12). The standard protein sample for ELISA was diluted with assay buffer at 1:50 to create standard curve. After dilution with phosphate-buffered saline (PBS) (pH 7.2) at 1:100, the samples were mixed with 100 µl of sample solution and 50 µl of detection solution, and incubated for 2 h at room temperature. Then, TMB chromogenic substrate was added and light absorption was measured at 495 nm. CD44V6 concentration was calculated according to the standard curve. The primary mouse monoclonal CD44V6 antibody (dilution, 1:500; cat. no. ab78960) and secondary goat anti-rabbit (HRP) IgG antibody (dilution, 1:2000; cat. no. ab6721) were from Abcam (Cambridge, MA, USA).

**Western blot analysis.** Total protein in the sample was extracted with the protein extraction kit from Roche according to the manufacturer’s recommendations. Then, we proceeded with standard western blot analysis procedures.

**Immunohistochemistry.** Immunohistochemistry SP-linking method was applied in this study. Normal ovarian tissue, benign ovarian tumor, and ovarian cancer samples were fixed in 10% formaldehyde, embedded in paraffin, and sectioned at 4 µm. The sections were fixed on a glass slide and placed in an oven for 2 h at 60˚C. Then, we de-paraffinized with xylene, re-dehydrated in ethyl alcohol gradients, and hydrated by washing in PBS 5 times, heated and boiled for 2 min in a pressure cooker. After cooling, the sections were placed in PBS for 30 min at room temperature. Then, we added 50 µl of peroxidase blocker, incubated at 37˚C for 10 min, and washed in PBS 5 times. PBS solution was removed, and 45 µl of pre-immune serum was added and incubated for 10 min at room temperature. Then, primary antibody was added and incubated at room temperature for 2 h (or overnight at 4˚C), and washed 5 times in PBS; 50 µl of streptomyein-HRP was added and incubated for 2 h at room temperature, and washed 5 times in PBS; and 100 µl of coloration solution was added and observed under the microscope. After 10 min, followed washing with distilled water and re-dyeing by hematoxylin for 5 min, washing again, dehydration in ethyl alcohol gradient, air drying, and then the slides were sealed.

**Quantification of stained slides.** Positive immunohistochemical staining is the accumulation of yellow particles in membrane or cytoplasm, which was judged as positive. The standards for immunohistochemistry showed (9) that membrane stain <10% or negative tumor cells after stained were determined as negative. Only the stained membrane or tumor cell with membrane stain >10% was identified as positive. The results were judged through the KI index, which was the numbers of positive cells in each field.

**Statistical analysis.** SPSS 20.0 software (Chicago, IL, USA) was used to process and analyze the data. CD44V6 protein expression in different tissue samples was detected by $\chi^2$. The result of immunohistochemistry KI index was tested by t-test.

**Results**

**CD44V6 mRNA expression.** To determine the role of CD44V6 in ovarian cancer, we examined CD44V6 mRNA levels in ovarian cancer, and benign and normal ovaries. Compared with normal ovaries, MEG-A3 mRNA content in benign ovarian tumor and ovarian cancer were higher. CD44V6 mRNA expression in benign ovarian tumor was 4.5 times
CD44V6 protein expression by western blot analysis. After identifying strong upregulation of CD44V6 at the mRNA level, we examined the expression of CD44V6 protein by western blot analysis in normal ovarian tissue, benign ovarian tumor, and ovarian cancer. We found no significant difference in the expression of CD44V6 protein between normal ovarian tissue and benign ovarian tumors (Fig. 2). However, CD44V6 protein content in ovarian cancer tissue was significantly higher compared with normal ovarian tissue and benign ovarian tumors (Fig. 2), which is consistent with the upregulation of CD44V6 mRNA.

CD44V6 protein expression by ELISA. After identifying strong upregulation of CD44V6 protein in ovarian cancer by western blot analysis, we verified this result using a more quantitative technique. We found no significant difference in CD44V6 protein expression between normal ovarian tissue and benign ovarian tumors (Table II). However, CD44V6 expression was significantly higher in ovarian cancer tissue than in normal ovaries and in benign ovarian tumors (Table II). This further supports the association of CD44V6 protein with ovarian cancer.

CD44V6 immunohistochemistry. To examine the accumulation and distribution of CD44V6, we conducted immunohistochemistry on normal ovarian tissue, benign ovarian tumor, and ovarian cancer (Table III). We found that CD44V6 was low in normal ovarian tissue and slightly higher in benign ovarian tumor, although the difference was not significant (Fig. 3 and Table III). However, we found a large number of CD44V6-positive cells in ovarian cancer (Fig. 3 and Table III). These results are consistent with the results with ELISA and western blot analysis.

Discussion

CD44V6 is an adhesive molecule that plays an important role in normal signal transduction and intercellular material exchange (13-15). Overexpression of CD44V is associated with malignant cell changes (16). Overexpression of CD44V can promote the incidence and deterioration of a malignant tumor to some extent (17). CD44V6 can be involved in the process of cell invasion and the transformation of tumor cells (18). Further research showed that CD44V6 can promote the fusion between capillary endothelial cells and tumor cells, which enables tumor cells to avoid the immune system and promote the transformation of tumor cells (19). In recent years, with research on gynecological diseases such as endometrial cancer, it was proposed that CD44V could be involved in the

Table III. CD44V6-positive cells in normal ovarian tissue, benign ovarian tumor, and ovarian cancer.

| Groups                | Total no. of cells (n) | CD44V6-positive cells | CD44V6-positive cells | KI value (%) | P-value  |
|-----------------------|------------------------|-----------------------|-----------------------|--------------|----------|
| Normal ovarian tissue | 400                    | 35                    | 365                   | 8.75         | >0.05    |
| Benign ovarian tumor  | 400                    | 51                    | 349                   | 12.75        | <0.05    |
| Ovarian cancer        | 400                    | 328                   | 72                    | 82.0         | <0.01    |

P<0.05, the difference is statistically significant.

Figure 2. CD44V6 expression of in normal ovarian tissue, benign ovarian tumor and ovarian cancer. Lane A, normal ovarian tissue; lane B, benign ovarian tumor; lane C, ovarian cancer.

Figure 3. CD44V6 immunohistochemistry in normal ovarian tissue, benign ovarian tumor and ovarian cancer. (A) Normal ovarian tissue. (B) Benign ovarian tumor. (C) Ovarian cancer.
incidence and progression of many gynecological diseases. For instance, CD44V expression in cervical cancer tissue is significantly higher than that of normal tissue (20).

The growing incidence of ovarian cancer has resulted in more studies and relevant molecular and cellular discoveries. In the present study, we found that CD44V6 is highly expressed in ovarian cancer, suggesting that a high expression of CD44V6 can promote the incidence and progression of ovarian cancer. Moreover, we found that CD44V6 mRNA levels are significantly higher in benign ovarian tumor compared to normal ovaries, but there was no difference at the protein level. These results suggest a close connection with the transformation of ovarian tissue, where CD44V6 mRNA is first upregulated in benign tumor and higher upregulation in malignant tumor results in elevated CD44V6. Thus, CD44V6 expression is strongly associated with the tumorous transformation of ovarian cells. Together with research in other cancers, these results suggest that CD44V6 is directly responsible for the transition from normal ovary to benign tumor to cancer. Understanding the role of CD44V6 in ovarian cancer can help in designing tests to improve early diagnosis and treatment of advanced-stage ovarian cancer.

References

1. Zhang X, Ng WL, Wang P, Tian L, Werner E, Wang H, Doetsch P and Wang Y: MicroRNA-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNFα. Cancer Res 72: 4707-4713, 2012.
2. Ouyang YB, Lu Y, Yue S and Giffard RG: miR-181 targets multiple Bcl-2 family members and induces apoptosis and mitochondrial function in astrocytes. Mitochondrion 12: 213-219, 2012.
3. Webb PM, Purdie DM, Grover S, Jordan S, Dick ML and Green AC: Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol 92: 232-239, 2004.
4. Singer CF, Tea MK, Pristauz G, Hubalek M, Rappaport C, Riedl C and Helbich T: Guideline for the prevention and early detection of breast and ovarian cancer in high risk patients, particularly in women from HBOC (hereditary breast and ovarian cancer) families. Wien Klin Wochenschr 124: 334-339, 2012 (In German).
5. Yu P, Zhou L, Ke W and Li K: Clinical significance of pAKT and CD44v6 overexpression with breast cancer. J Cancer Res Clin Oncol 136: 1283-1292, 2010.

6. Afify A, Purnell P and Nguyen L: Role of CD44a and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol 86: 95-100, 2009.
7. Liang J, Jiang D, Griffith J, Yu S, Fan J, Zhao X, Bucala R and Noble PW: CD44 is a negative regulator of acute pulmonary inflammation and lipopolysaccharide-TLR signaling in mouse macrophages. J Immunol 178: 2469-2475, 2007.
8. Matsumura Y, Hanbury D, Smith J and Tarin D: Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. BMJ 308: 619-624, 1994.
9. Li J, Zha XM, Wang R, Li XD, Xu B, Xu YJ and Yin YM: Regulation of CD44 expression by tumor necrosis factor-α and its potential role in breast cancer cell migration. Biomed Pharmacother 66: 144-150, 2012.
10. Nagel S, Hirschmann P, Dirnhofer S, Günther U and Tzankov A: Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. Exp Hematol 38: 38-45, 2010.

11. Shi J, Zhou Z, Di W and Li N: Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer 13: 182, 2013.
12. Zhao S, He JL, Qiu ZX, Chen NY, Luo Z, Chen BJ and Li WM: Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: a meta-analysis. Asian Pac J Cancer Prev 15: 6761-6766, 2014.
13. Jung T, Gross W and Zöller M: CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem 286: 15862-15874, 2011.
14. Wang J, Xiao L, Luo CH, Zhou H, Zeng L, Zhong J, Tang Y, Zhao XH, Zhao M and Zang Y: CD44v6 promotes β-catenin and TGF-β expression, inducing aggression in ovarian cancer cells. Mol Med Rep 11: 3505-3510, 2015.
15. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR and Ghatak S: Hyaluronan-CD44 interactions as potential targets for cancer therapy, FEBS J 278: 1429-1443, 2011.
16. Heider KH, Kuthan H, Stehle G and Munzert G: CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 53: 567-579, 2004.
17. Marhaba R and Zöller M: CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35: 211-231, 2004.
18. Spiegelberg D, Kuku G, Selvaraju R and Nestor M: Characterization of CD44 variant expression in head and neck squamous cell carcinomas. Tumour Biol 35: 2053-2062, 2014.
19. Ponta H, Sherman L and Herrlich PA: CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4: 33-45, 2003.
20. Rassouli FB, Matin MM, Bahrami AR, Ghaffarzadegan K, Cheshomi H, Lari S, Memar B and Kan MS: Evaluating stem and cancerous biomarkers in CD15-CD44+ KYSE30 cells. Tumour Biol 34: 2909-2920, 2013.